Gemcitabine is widely used to treat ovarian cancer and augments the effect of AZD1775 22, while olaparib improves progression‐free survival for ovarian cancer patients with BRCA1/2 mutations 30, 31 and is synergistic with AZD1775 23. Here, BRCA1 is linked to ovarian carcinoma.